Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clinically Isolated Syndrome Clear all
Completed No phase listed Observational

Mitochondrial Dysfunction and Disease Progression

NCT02549703
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 21, 2026, 10:44 PM EDT
Terminated No phase listed Observational

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976
View directory record Official record
Conditions
Relapsing Forms of MS
Interventions
Diroximel Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

NCT04998851
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational

Natural History of Multiple Sclerosis and Its Mimickers

NCT02504840
View directory record Official record
Conditions
Neurologic Disorders, Healthy Volunteers, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 10:44 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biobank For MS And Other Demyelinating Diseases

NCT00445367
View directory record Official record
Conditions
Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Other
Eligibility
Not listed
Enrollment
3,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2036
U.S. locations
10
States / cities
Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 10:44 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Subjects With Optic Neuritis

NCT00624468
View directory record Official record
Conditions
Optic Neuritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 21, 2026, 10:44 PM EDT
Active, not recruiting Phase 4 Interventional

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Not applicable Interventional

Prebiotic vs Probiotic in Multiple Sclerosis

NCT04038541
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Interventions
Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene Expression Profiles in Multiple Sclerosis (MS)

NCT00704834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 21, 2026, 10:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

NCT01396343
View directory record Official record
Conditions
Pediatric Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 21 Years
Enrollment
1,276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Not applicable Interventional

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

NCT00137176
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2009 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

NCT04998812
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 10:44 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
View directory record Official record
Conditions
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational

Ocrelizumab in Breastmilk

NCT04387110
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 21, 2026, 10:44 PM EDT
Not listed No phase listed Observational

Risk Factors in Early Multiple Sclerosis

NCT03586986
View directory record Official record
Conditions
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Interventions
Brain MRI
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
300 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Phase 4 Interventional

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

NCT00146068
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex/Zocor
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 21, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 21, 2026, 10:44 PM EDT
Active, not recruiting Not applicable Interventional

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

NCT04009005
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Interventions
Therapeutic diet and lifestyle
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 21, 2026, 10:44 PM EDT
Completed No phase listed Observational

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 21, 2026, 10:44 PM EDT